Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America
Autor: | Gavin Cloherty, Mauricio Lisker-Melman, Mandana Khalili, Harry L.A. Janssen, Wendy C. King, Richard K. Sterling, Marc G. Ghany, William M. Lee, Raymond T. Chung, Anna S.F. Lok, Daryl T.-Y. Lau, Norah A. Terrault |
---|---|
Rok vydání: | 2021 |
Předmět: |
Adult
Male HBsAg Hepatitis B virus Genotype medicine.disease_cause Hepatitis B Chronic Chronic hepatitis Antigen Medicine Humans Hepatitis B e Antigens Hepatitis B Surface Antigens Hepatology medicine.diagnostic_test business.industry virus diseases RNA Alanine Transaminase Hepatitis B Middle Aged medicine.disease Virology Hepatitis B Core Antigens digestive system diseases Cross-Sectional Studies HBeAg Immunoassay DNA Viral North America RNA Viral Female business Biomarkers Follow-Up Studies |
Zdroj: | Hepatology (Baltimore, Md.). 74(5) |
ISSN: | 1527-3350 |
Popis: | BACKGROUND AND AIMS The clinical utility of two biomarkers, hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg), as compared to conventional markers of HBV replication and disease activity, is unclear. APPROACH AND RESULTS Untreated participants in the North American Hepatitis B Research Network Adult Cohort Study were categorized by chronic hepatitis B (CHB) phases based on HBsAg and HBeAg status and HBV DNA and alanine aminotransferase (ALT) levels. HBV RNA and HBcrAg were measured (Abbott HBV pgRNA Research Assay and Fujirebio Lumipulse Immunoassay, respectively), and cross-sectional associations with conventional CHB markers were tested. Among 1,409 participants across all CHB phases, median HBV DNA was 3.8 log10 IU/mL and ALT was 34 U/L. HBV RNA was quantifiable in 99% of HBeAg+ and 58% of HBeAg- participants; HBcrAg was quantifiable in 20% of HBeAg+ (above linear range in the other 80%) and 51% of HBeAg- participants. Both markers differed across CHB phases (P |
Databáze: | OpenAIRE |
Externí odkaz: |